{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:12:54Z","timestamp":1778638374748,"version":"3.51.4"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006134","name":"Foundation for Promotion of Material Science and Technology of Japan","doi-asserted-by":"publisher","award":["17\\u202FK08586"],"award-info":[{"award-number":["17\\u202FK08586"]}],"id":[{"id":"10.13039\/501100006134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006134","name":"Foundation for Promotion of Material Science and Technology of Japan","doi-asserted-by":"publisher","award":["20\\u202FK17776"],"award-info":[{"award-number":["20\\u202FK17776"]}],"id":[{"id":"10.13039\/501100006134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006134","name":"Foundation for Promotion of Material Science and Technology of Japan","doi-asserted-by":"publisher","award":["23\\u202FK15607"],"award-info":[{"award-number":["23\\u202FK15607"]}],"id":[{"id":"10.13039\/501100006134","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bcp.2024.116232","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T01:54:51Z","timestamp":1713578091000},"page":"116232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Challenging and target-based shifting strategies for heart failure treatment: An update from the last decades"],"prefix":"10.1016","volume":"224","author":[{"given":"Yuichi","family":"Hattori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/ijerph13020238","article-title":"Prevalence of heart failure and adherence to process indicators: which socio-demographic determinations are involved?","volume":"13","author":"Buja","year":"2016","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"15","key":"10.1016\/j.bcp.2024.116232_b0010","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"17","key":"10.1016\/j.bcp.2024.116232_b0015","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2024.116232_b0020","doi-asserted-by":"crossref","unstructured":"P. Ponikowski,A.A. Voors,Stefan, D. Anker,H. Bueno,J.G.F. Cleland,A.J.S. Coats,V. Falk,J.R. Gonz\u00e1lez-Juanatey,V.-P. Harjola,E.A. Jankowska,M. Jessup,C. Linde,P. Nihoyannopoulos,J.T. Parissis,B. Pieske,J.P. Riley,G.M.C. Rosano,L.M. Ruilope,F. Ruschitzka,F.H. Rutten,P. van der Meer,ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 37 (27) (2016) 2129-2200.","DOI":"10.1093\/eurheartj\/ehw128"},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12889-019-7934-3","article-title":"Queen of Hearts and RECONNECT investigators, Mortality after hospital admission for heart failure: improvement over time, equally strong in women as in men","volume":"20","author":"Buddeke","year":"2020","journal-title":"BMC Public Health"},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0030","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2589-7500(22)00045-0","article-title":"Predicting hospitalisation for heart failure before first hospitalisation: a retrospective model development and external validation study","volume":"4","author":"Bradley","year":"2022","journal-title":"Lancet Digit Health."},{"key":"10.1016\/j.bcp.2024.116232_b0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/amj.2020.03.03","article-title":"Global epidemiology and future trends of heart failure","volume":"5","author":"Lippi","year":"2020","journal-title":"AME Med. J."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005082-200007000-00002","article-title":"Cellular events linked to cardiac remodeling in heart failure: targets for pharmacologic intervention","volume":"14","author":"Piano","year":"2000","journal-title":"J. Cardiovasc. Nurs."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.47102\/annals-acadmedsg.V33N4p444","article-title":"Medical therapy in heart failure \u2014 is polypharmacy necessary?","volume":"33","author":"Kwok","year":"2004","journal-title":"Ann. Acad. Med. Singap."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"issue":"24","key":"10.1016\/j.bcp.2024.116232_b0055","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.jacc.2012.06.062","article-title":"Myocardial recovery: myth, magic or molecular target?","volume":"60","author":"Mann","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0060","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10741-021-10137-2","article-title":"Current and emerging drug targets in heart failure treatment","volume":"27","author":"Ghionzoli","year":"2022","journal-title":"Heart Fail. Rev."},{"issue":"16","key":"10.1016\/j.bcp.2024.116232_b0065","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/mt.2008.89","article-title":"SERCA2a gene therapy for heart failure: ready for primetime?","volume":"16","author":"Periasamy","year":"2008","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0300-8932(10)70030-0","article-title":"Gene therapy for heart failure: An investigational treatment that is coming of age","volume":"63","author":"Mancini","year":"2010","journal-title":"Rev. Esp. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0075","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11897-018-0410-z","article-title":"Gene therapy for heart failure: New perspectives","volume":"15","author":"Gabisonia","year":"2018","journal-title":"Curr. Heart Fail. Rep."},{"issue":"10","key":"10.1016\/j.bcp.2024.116232_b0080","doi-asserted-by":"crossref","first-page":"e012239","DOI":"10.1161\/JAHA.119.012239","article-title":"Current landscape of heart failure gene therapy","volume":"8","author":"Kieserman","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cvr\/cvv205","article-title":"Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation","volume":"108","author":"Rincon","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"21","key":"10.1016\/j.bcp.2024.116232_b0090","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/eurheartj\/ehw019","article-title":"Gene therapy for the treatment of heart failure: promise postponed","volume":"37","author":"Hulot","year":"2016","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0095","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.tcm.2016.11.003","article-title":"Editorial Commentary: Clinical gene therapy trials for heart failure: Did they fail?","volume":"27","author":"Watanabe","year":"2017","journal-title":"Trends Cardiovasc. Med."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.18609\/cgti.2020.073","article-title":"Consideration of clinical translation of cardiac AAV gene therapy","volume":"6","author":"Yamada","year":"2020","journal-title":"Cell Gene Ther Insights."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00055601","article-title":"Digitalis and heart failure: does digitalis really produce beneficial effects through a positive inotropic action?","volume":"6","author":"Bolognesi","year":"1992","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b0110","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0146-2806(96)80001-6","article-title":"The use of digitalis in heart failure","volume":"21","author":"Rahimtoola","year":"1996","journal-title":"Curr. Probl. Cardiol."},{"issue":"24","key":"10.1016\/j.bcp.2024.116232_b0115","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1161\/01.CIR.0000132477.32438.03","article-title":"Digitalis therapy for patients in clinical heart failure","volume":"109","author":"Rahimtoola","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0120","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0735-1097(93)90403-N","article-title":"Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of PROVED trial. PROVED Investigative Group","volume":"22","author":"Uretsky","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199307013290101","article-title":"Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors","volume":"329","author":"Packer","year":"1993","journal-title":"RADIANCE Study. N Engl J Med."},{"issue":"8","key":"10.1016\/j.bcp.2024.116232_b0130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"Digitalis Investigation Group","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0135","first-page":"613","article-title":"Digoxin therapy for heart failure: an update","volume":"74","author":"Morris","year":"2006","journal-title":"Am. Fam. Physician"},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0140","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1001\/jama.2020.24578","article-title":"Digitalis glycosides for heart rate control in atrial fibrillation","volume":"324","author":"Curfman","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.bcp.2024.116232_b0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijcard.2020.04.047","article-title":"AF-CHF Investigators, Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillations and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis","volume":"313","author":"Elayi","year":"2020","journal-title":"Int. J. Cardiol."},{"issue":"23","key":"10.1016\/j.bcp.2024.116232_b0150","first-page":"e199","article-title":"ACC\/AHA Task Force Members, 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0155","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2024.116232_b0160","first-page":"S68","article-title":"Diuretic management in heart failure","volume":"16","author":"Felker","year":"2010","journal-title":"Congest. Heart Fail."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.15420\/ecr.2015.10.01.42","article-title":"Diuretic therapy in heart failure \u2013 Current approaches","volume":"10","author":"Casu","year":"2015","journal-title":"Eur Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/00015385.2021.1878423","article-title":"Diuretic therapy in congestive heart failure","volume":"77","author":"Kennelly","year":"2022","journal-title":"Acta Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"10.1016\/j.bcp.2024.116232_b0180","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0185","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacc.2008.03.046","article-title":"Vasodilator therapy for decompensated heart failure","volume":"52","author":"Yancy","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0190","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10741-007-9017-2","article-title":"Vasodilators in acute heart failure","volume":"12","author":"Hollenberg","year":"2007","journal-title":"Heart Fail. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2024.116232_b0195","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejhf.123","article-title":"The role of intravenous vasodilators in acute heart failure management","volume":"16","author":"Piper","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"16","key":"10.1016\/j.bcp.2024.116232_b0200","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0735-1097(83)80018-7","article-title":"Vasodilator therapy for acute myocardial infarction and chronic congestive heart failure","volume":"1","author":"Chatterjee","year":"1983","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"10.1016\/j.bcp.2024.116232_b0210","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","volume":"314","author":"Cohn","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2024.116232_b0215","first-page":"S129","article-title":"15 years of heart-failure trials: what have we learned?","volume":"352","author":"Massie","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0220","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/j.1552-4604.1995.tb04087.x","article-title":"Calcium antagonists use in congestive heart failure: still a bridge too far?","volume":"35","author":"Piepho","year":"1995","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2024.116232_b0225","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","article-title":"Calcium channel blockers","volume":"13","author":"Elliott","year":"2011","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2024.116232_b0230","first-page":"110","article-title":"Vasodilators for heart failure \u2014 \u2014 useful or useless?","volume":"75","author":"Franciosa","year":"1988","journal-title":"Cardiology"},{"issue":"13","key":"10.1016\/j.bcp.2024.116232_b0235","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1056\/NEJM198409273111310","article-title":"The adrenergic nervous system in heart failure","volume":"311","author":"Bristow","year":"1984","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0240","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/01.RES.69.5.1185","article-title":"Cardiac myocyte necrosis induced by angiotensin II","volume":"69","author":"Tan","year":"1991","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.bcp.2024.116232_b0245","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.CIR.100.9.999","article-title":"Mechanisms and models in heart failure: A combinatorial approach","volume":"100","author":"Mann","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0250","first-page":"250","article-title":"The neurohormonal overactivity syndrome in heart failure","volume":"13","author":"Xanthopoulos","year":"2023","journal-title":"Life (basel)"},{"issue":"9) (Suppl 2","key":"10.1016\/j.bcp.2024.116232_b0255","doi-asserted-by":"crossref","first-page":"9J","DOI":"10.1016\/S0002-9149(97)00832-1","article-title":"The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease","volume":"80","author":"Cody","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bcp.2024.116232_b0260","doi-asserted-by":"crossref","unstructured":"P. Ponikowski,A.A. Voors,S.D. Anker,H. Bueno,J.G.F. Cleland,A.J.S. Coats,V. Falk,J.R. Gonz\u00e1lez-Juanatey,V.-P. Harjola,E.A. Jankowska,M. Jessup,C. Linde,P. Nihoyannopoulos,J.T. Parissis,B. Pieske,J.P. Riley,G.M.C. Rosano,L.M. Ruilope,F. Ruschitzka,F.H. Rutten,P. van der Meer,Authors\/Task Force Members,Document Reviewers, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 18 (8) (2016) 891-975.","DOI":"10.1002\/ejhf.592"},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0265","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0270","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: Defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.bcp.2024.116232_b0275","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fphys.2013.00323","article-title":"New advances in beta-blocker therapy in heart failure","volume":"4","author":"Barrese","year":"2013","journal-title":"Front. Physiol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0280","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","article-title":"Adrenergic nervous system in heart failure: pathophysiology and therapy","volume":"113","author":"Lymperopoulos","year":"2013","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b0285","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/01.CIR.0000065187.80707.18","article-title":"\u03b2-Blockers in chronic heart failure","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.bcp.2024.116232_b0290","first-page":"101","article-title":"The use of \u03b2-blockers in heart failure with reduced ejection fraction","volume":"8","author":"Masarone","year":"2021","journal-title":"J Cardiovasc Dev Dis."},{"key":"10.1016\/j.bcp.2024.116232_b0295","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2021.03.035","article-title":"The use of \u03b2-blockers in patients with heart failure and comorbidities: Doubts, certainties and unsolved issues","volume":"88","author":"Paolillo","year":"2021","journal-title":"Eur. J. Intern. Med."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0300","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1388-9842(02)00025-9","article-title":"Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET","volume":"4","author":"Poole-Wilson","year":"2002","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"SENIORS Investigators, Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur. Heart J."},{"issue":"20","key":"10.1016\/j.bcp.2024.116232_b0310","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jacc.2017.03.563","article-title":"Achieving a maximally tolerated \u03b2-blocker dose in heart failure patients","volume":"69","author":"Bhatt","year":"2017","journal-title":"J Am Col Cardiol."},{"key":"10.1016\/j.bcp.2024.116232_b0315","first-page":"2","article-title":"Median inertia in the optimization of heart failure treatment after discharge and its relationship to outcome","volume":"6","author":"Berthelot","year":"2018","journal-title":"Health Care Curr Rev."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0320","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cardfail.2018.10.005","article-title":"Low utilization of beta blockers among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction","volume":"25","author":"Loop","year":"2019","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.bcp.2024.116232_b0325","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurheartj\/15.suppl_D.68","article-title":"Tissue angiotensin II system in the human heart","author":"Urata","year":"1994","journal-title":"Eur Heart J. Suppl D"},{"issue":"8A","key":"10.1016\/j.bcp.2024.116232_b0330","doi-asserted-by":"crossref","first-page":"10C","DOI":"10.1016\/S0002-9149(01)01507-7","article-title":"Angiotension II and the pathophysiology of cardiovascular remodeling","volume":"87","author":"Williams","year":"2001","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0335","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1368-5031.2005.00513.x","article-title":"A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure","volume":"59","author":"Erhardt","year":"2005","journal-title":"Int. J. Clin. Pract."},{"issue":"9215","key":"10.1016\/j.bcp.2024.116232_b0340","first-page":"1575","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather","year":"2000","journal-title":"ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet."},{"issue":"17","key":"10.1016\/j.bcp.2024.116232_b0345","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/euhj.2001.2783","article-title":"Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology, Guidelines for the diagnosis and treatment of chronic heart failure","volume":"22","author":"Remme","year":"2001","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.bcp.2024.116232_b0350","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.bcp.2024.116232_b0355","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/euhj.1998.1481","article-title":"Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry","volume":"20","author":"Bart","year":"1999","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.bcp.2024.116232_b0360","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ehj.2004.06.003","article-title":"Task Force on ACE-inhibitors of the European Society of Cardiology, Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology","volume":"25","author":"L\u00f3pez-Send\u00f3n","year":"2004","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0365","first-page":"H1769","article-title":"Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations","volume":"273","author":"Balcells","year":"1997","journal-title":"Am. J. Phys. Anthropol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0370","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"issue":"Suppl J","key":"10.1016\/j.bcp.2024.116232_b0375","doi-asserted-by":"crossref","first-page":"J10","DOI":"10.1093\/eurheartj\/sui057","article-title":"The role of angiotensin II receptor blockers in the management of heart failure","volume":"7","author":"McMurray","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2024.116232_b0380","doi-asserted-by":"crossref","unstructured":"P. Ponikowski,A.A. Voors,S.D. Anker,H. Bueno,J.G.F. Cleland,A.J.S Coats,V. Falk,J.R. Gonz\u00e1lez-Juanatey,V.-P. Harjola,E.A. Jankowska,M. Jessup,C. Linde,P. Nihoyannopoulos,J.T. Parissis,B. Pieske,J.P. Riley,G.M.C. Rosano,L.M. Ruilope,F. Ruschitzka,F.H. Rutten,P. van der Meer, 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Eng Ed). 69 (12) (2016) 1167.","DOI":"10.1016\/j.rec.2016.11.005"},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0385","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0002-8703(00)90037-1","article-title":"Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors","volume":"139","author":"Granger","year":"2000","journal-title":"Am. Heart J."},{"issue":"10","key":"10.1016\/j.bcp.2024.116232_b0390","first-page":"1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study","volume":"100","author":"McKelvie","year":"1999","journal-title":"The RESOLVD Pilot Study Investigators. Circulation."},{"issue":"9386","key":"10.1016\/j.bcp.2024.116232_b0395","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"CHARM Investigators and Committees, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0400","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.EBP.0000540311.89554.88","article-title":"Is combining ACE inhibitors and ARBs helpful or harmful?","volume":"16","author":"Gibbs","year":"2013","journal-title":"Evidence-Based Practice."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0405","doi-asserted-by":"crossref","first-page":"e9946","DOI":"10.1371\/journal.pone.0009946","article-title":"Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure","volume":"5","author":"Kuenzli","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.bcp.2024.116232_b0410","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0415","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bcp.2024.116232_b0420","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.bcp.2024.116232_b0425","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"TOPCAT Investigators, Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2024.116232_b0430","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/01.CIR.65.7.1382","article-title":"Drug-induced conditioning in congestive heart failure","volume":"65","author":"Leier","year":"1982","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0435","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.88.6.2941","article-title":"Medical advances in the treatment of congestive heart failure","volume":"88","author":"Armstrong","year":"1993","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0440","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/13543780902922660","article-title":"Current drugs and medical treatment algorithms in the management of acute decompensated heart failure","volume":"18","author":"Triposkiadis","year":"2009","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0445","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00134-011-2435-6","article-title":"Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Tacon","year":"2012","journal-title":"Intensive Care Med."},{"issue":"9","key":"10.1016\/j.bcp.2024.116232_b0450","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/ejhf.1557","article-title":"Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials","volume":"21","author":"Ahmad","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0455","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.CIR.82.3.774","article-title":"Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group","volume":"82","author":"Uretsky","year":"1990","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b0460","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators, Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"J. Am. Med. Assoc."},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b0465","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1253\/circj.CJ-08-0838","article-title":"Cardiac Ca2+ signaling and Ca2+ sensitizers","volume":"72","author":"Endoh","year":"2008","journal-title":"Circ J"},{"issue":"46","key":"10.1016\/j.bcp.2024.116232_b0470","doi-asserted-by":"crossref","first-page":"28584","DOI":"10.1016\/S0021-9258(19)61945-9","article-title":"Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modeling, fluorescence probe, and proton nuclear magnetic resonance study","volume":"269","author":"Pollesello","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0475","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.RES.77.1.107","article-title":"Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart","volume":"77","author":"Edes","year":"1995","journal-title":"Circ. Res."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2024.116232_b0480","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00005344-199506261-00003","article-title":"Mechanisms of action of calcium-sensitizing drugs","volume":"26","author":"Haikala","year":"1995","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0485","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1067\/mcp.2000.110972","article-title":"Myocardial efficiency during levosimendan infusion in congestive heart failure","volume":"68","author":"Ukkonen","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0490","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"REVIVE Heart Failure Study Group, Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.bcp.2024.116232_b0495","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.15420\/cfr.2020.03","article-title":"Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use","volume":"6","author":"Papp","year":"2020","journal-title":"Card. Fail. Rev."},{"key":"10.1016\/j.bcp.2024.116232_b0500","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2147\/DDDT.S295214","article-title":"Evidence and current use of levosimendan in the treatment of heart failure: Filling the gap","volume":"15","author":"Conti","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"issue":"21","key":"10.1016\/j.bcp.2024.116232_b0505","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.3390\/jcm11216408","article-title":"Use of levosimendan in patients with advanced heart failure: An update","volume":"11","author":"Masarone","year":"2022","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0510","first-page":"4820","article-title":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. ESC","volume":"8","author":"Garc\u00eda-Gonz\u00e1lez","year":"2021","journal-title":"Heart Fail."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jphs.CP0060010","article-title":"Vasodilating mechanisms of levosimendan: Involvement of K+ channels","volume":"104","author":"Yildiz","year":"2007","journal-title":"J. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0520","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1160\/TH14-06-0549","article-title":"Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro","volume":"113","author":"Krychtik","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcp.2024.116232_b0525","doi-asserted-by":"crossref","first-page":"9704","DOI":"10.1038\/srep09704","article-title":"Levosimendan displays anti-inflammatory effects MPO bioavailability in patients with severe heart failure","volume":"5","author":"Adam","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116232_b0530","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2017.02.040","article-title":"Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: Novel therapeutic implications and changes","volume":"177","author":"Hattori","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0535","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1186\/s13054-014-0652-4","article-title":"Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model","volume":"18","author":"Tsao","year":"2014","journal-title":"Crit. Care"},{"issue":"11","key":"10.1016\/j.bcp.2024.116232_b0540","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1097\/CCM.0000000000001269","article-title":"Anti-inflammatory profile of levosimendan in cecal-ligation-induced septic mice and lipopolysaccharide-stimulated macrophages","volume":"43","author":"Wang","year":"2015","journal-title":"Crit. Care Med."},{"issue":"9","key":"10.1016\/j.bcp.2024.116232_b0545","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00210-018-1527-z","article-title":"Cardioprotective and functional effects of levosimendan and milrinone in mice with cecal ligation and puncture-induced sepsis","volume":"391","author":"Yamashita","year":"2018","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0550","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjp.2008.328","article-title":"Effects of levo- and dextrosimendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli","volume":"155","author":"Sareila","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"17","key":"10.1016\/j.bcp.2024.116232_b0555","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","article-title":"Levosimendan for the prevention of acute organ dysfunction in sepsis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0560","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1399-6576.2005.00541.x","article-title":"Successful reversal of resistant hypodynamic septic shock with levosimendan","volume":"49","author":"Matejovic","year":"2005","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0565","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00134-005-2619-z","article-title":"Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression","volume":"31","author":"Morelli","year":"2005","journal-title":"Intensive Care Med."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0570","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/life13061346","article-title":"Levosimendan in the treatment of patients with severe septic cardiomyopathy","volume":"13","author":"Tsolaki","year":"2023","journal-title":"Life (basal)"},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0575","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10741-009-9135-0","article-title":"A novel approach to improve cardiac performace: cardiac myosin activators","volume":"14","author":"Teerlink","year":"2009","journal-title":"Heart Fail. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0580","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41467-017-00176-5","article-title":"Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbi","volume":"8","author":"Planelles-Herrero","year":"2017","journal-title":"Nat. Commun."},{"issue":"10062","key":"10.1016\/j.bcp.2024.116232_b0585","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"COSMIC-HF Investigators, Chonic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0590","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"GALACTIC-HF Investigators, Cardiac myosin activation with omecamtive mecarbil in systolic heart failure","volume":"348","author":"Teerlink","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"48","key":"10.1016\/j.bcp.2024.116232_b0595","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1093\/eurheartj\/ehac293","article-title":"Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial","volume":"43","author":"Metra","year":"2022","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0600","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","article-title":"Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: A post hoc analysis of data from the GALACTIC-HF randomized clinical trial","volume":"7","author":"Felker","year":"2022","journal-title":"JAMA Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0605","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2022.11016","article-title":"Effect of omecamtiv mecarbil on excise capacity in chronic heart failure with reduced ejection fraction: The METEORIC-HF randomized clinical trial","volume":"328","author":"Lewis","year":"2022","journal-title":"J. Am. Med. Assoc."},{"issue":"22","key":"10.1016\/j.bcp.2024.116232_b0610","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1001\/archinte.163.22.2696","article-title":"Role of the natriuretic peptide system in cardiorenal protection","volume":"163","author":"McFalane","year":"2003","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0615","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bcp.2024.116232_b0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107863","article-title":"The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications","volume":"227","author":"Kuwahara","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0625","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","article-title":"Neprilysin inhibitors in heart failure: The science, mechanism of action, clinical studies, and unanswered questions","volume":"8","author":"Bozkurt","year":"2022","journal-title":"JACC Basic Transl Sci."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0630","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A test in context: Neprilysin: Function, inhibition and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.bcp.2024.116232_b0635","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","article-title":"Natriuretic peptide metabolism, clearance and degradation","volume":"278","author":"Potter","year":"2011","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.bcp.2024.116232_b0640","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.recesp.2016.04.012","article-title":"Neprilysin: Indications, expectations, and challenges","volume":"69","author":"Bayes-Genis","year":"2016","journal-title":"Rev Esp Cardiol. (engl Ed)"},{"issue":"11","key":"10.1016\/j.bcp.2024.116232_b0645","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADISM-HF Investigators and Committees, Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0650","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.bcp.2024.116232_b0655","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"PARAGON-HF Investigators and Committees, Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"31","key":"10.1016\/j.bcp.2024.116232_b0660","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sucubitril\/valsartan in heart failure with mildly reduced a preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2024.116232_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106035","article-title":"Current and future therapeutic perspective in chronic heart failure","volume":"175","author":"Mascolo","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"36","key":"10.1016\/j.bcp.2024.116232_b0670","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Scientific Document Group, 2021ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.bcp.2024.116232_b0675","first-page":"1502","article-title":"Sodium-glucose cotransporter-2 inhibition and the glomerulus: A review","volume":"33","author":"Kalra","year":"2016","journal-title":"Avd Ther."},{"issue":"21","key":"10.1016\/j.bcp.2024.116232_b0680","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF Trial Committees and Investigators, Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.bcp.2024.116232_b0685","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-Reduced Trial Investigators, Cardiocascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.bcp.2024.116232_b0690","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-Preserved Trial Investigators, Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bcp.2024.116232_b0695","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0700","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12325-023-02652-5","article-title":"Potential underlying mechanisms explaining the cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors","volume":"41","author":"Verma","year":"2024","journal-title":"Adv. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2024.116232_b0705","doi-asserted-by":"crossref","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective effects of sirtuin-1 and its downstream effectors: Potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ. Heart Fail."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0710","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","article-title":"Nitric oxide signalling in cardiovascular health and disease","volume":"15","author":"Farah","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b0715","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0720","first-page":"452","article-title":"The role of nitric oxide in heart failure","volume":"8","author":"Macdonald","year":"1996","journal-title":"Potential for Pharmacological Intervention. Drugs Aging."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0725","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1527-5299.2002.00715.x","article-title":"The nitric oxide pathway and oxidative stress in heart failure","volume":"8","author":"Searles","year":"2002","journal-title":"Congest. Heart Fail."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0730","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail."},{"issue":"10","key":"10.1016\/j.bcp.2024.116232_b0735","doi-asserted-by":"crossref","first-page":"e004133","DOI":"10.1161\/JAHA.116.004133","article-title":"Heart failure, left ventricular remodeling, and circulating nitric oxide metabolites","volume":"5","author":"Chirinos","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"21","key":"10.1016\/j.bcp.2024.116232_b0740","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"J. Am. Med. Assoc."},{"issue":"15","key":"10.1016\/j.bcp.2024.116232_b0745","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"VITALITY-HFpEF Study Group, Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"15","key":"10.1016\/j.bcp.2024.116232_b0750","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: The CAPACITY HFpEF randomized clinical trial","volume":"324","author":"Udelson","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"20","key":"10.1016\/j.bcp.2024.116232_b0755","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"VICTORIA Study Group, Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0760","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40265-021-01496-z","article-title":"Vericiguat: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.bcp.2024.116232_b0765","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The clinical use of ivabradine","volume":"370","author":"Koruth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0770","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2005.01.005","article-title":"Physiology and pharmacology of the cardiac pacemaker (\u201cfunny\u201d) current","volume":"107","author":"Baruscotti","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2024.116232_b0775","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pbiomolbio.2021.06.010","article-title":"Regulation of sinoatrial funny channels by cyclic nucleotides: From adrenaline and IK2 to direct binding of ligands to protein subunits","volume":"166","author":"Xia","year":"2021","journal-title":"Prog. Biophys. Mol. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0780","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.phrs.2006.03.006","article-title":"Funny channels in the control of cardiac rhythm and mode of action of selective blockers","volume":"53","author":"DiFranceaco","year":"2006","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0785","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/ehi555","article-title":"Predictors of mortality and morbidity in patients with chronic heart failure","volume":"27","author":"Pocock","year":"2006","journal-title":"Eur. Heart J."},{"issue":"9641","key":"10.1016\/j.bcp.2024.116232_b0790","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"BEAUTIFUL Investigators, Ivabradine for patients with stable coronary disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"issue":"9744","key":"10.1016\/j.bcp.2024.116232_b0795","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"SHIFT Investigators, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0800","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.coph.2009.09.002","article-title":"The role of mitochondria in health and disease","volume":"9","author":"Johannsen","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0805","doi-asserted-by":"crossref","first-page":"C33","DOI":"10.1152\/ajpcell.00243.2006","article-title":"Role of cardiolipin alterations in mitochondrial dysfunction and disease","volume":"292","author":"Chicco","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"8","key":"10.1016\/j.bcp.2024.116232_b0810","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nchembio.2113","article-title":"Loss of protein association causes cardiolipin degradation in Barth syndrome","volume":"12","author":"Xu","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2024.116232_b0815","doi-asserted-by":"crossref","unstructured":"K.C. Chatfield, G.C. Sparagna, S. Chau, E.K. Phillips, A.V. Ambardekar, M. Aftab, M.B. Mitchell, C.C. Sucharov, S.D. Miyamoto, B.L. Stauffer, Elamipretide improves mitochondrial function in the failing human heart. JACC Basic Transl Sci. 4 (2) 147-157.","DOI":"10.1016\/j.jacbts.2018.12.005"},{"issue":"7","key":"10.1016\/j.bcp.2024.116232_b0820","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1194\/jlr.M600551-JLR200","article-title":"Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure","volume":"48","author":"Sparagna","year":"2007","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0825","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","article-title":"Expert consensus document: Mitochondrial function as a therapeutic target in heart failure","volume":"14","author":"Brown","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"issue":"8","key":"10.1016\/j.bcp.2024.116232_b0830","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/bph.12461","article-title":"First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics","volume":"171","author":"Szeto","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0835","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s42003-020-1101-3","article-title":"The cardiolipin-binding peptide elamipretide migrates fragmentation of cristae networks following cardiac ischemia reperfusion in rats","volume":"3","author":"Allen","year":"2020","journal-title":"Commun Biol."},{"key":"10.1016\/j.bcp.2024.116232_b0840","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lfs.2015.09.022","article-title":"Bendavia restores mitochondrial energy metabolism gene expression and suppresses cardiac fibrosis in the border zone of the infarcted heart","volume":"141","author":"Shi","year":"2015","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0845","doi-asserted-by":"crossref","first-page":"e002206","DOI":"10.1161\/CIRCHEARTFAILURE.115.002206","article-title":"Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure","volume":"9","author":"Sabbah","year":"2016","journal-title":"Circ. Heart Fail."},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b0850","doi-asserted-by":"crossref","first-page":"e004389","DOI":"10.1161\/CIRCHEARTFAILURE.117.004389","article-title":"Novel mitochondria-targeting peptide in heart failure treatment: A randomized, placebo-controlled trial of elamipretide","volume":"10","author":"Daubert","year":"2017","journal-title":"Circ. Heart Fail."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b0855","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cardfail.2020.02.001","article-title":"Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial","volume":"26","author":"Butler","year":"2020","journal-title":"J Cardiol Fail."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0860","first-page":"9","volume":"7","author":"Ecker","year":"2015","journal-title":"The Therapeutic Monoclonal Antibody Market. Mabs."},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0865","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.CIR.93.4.704","article-title":"Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart","volume":"93","author":"Torre-Amione","year":"1996","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.bcp.2024.116232_b0870","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","article-title":"Framingham Heart Study, Inflammatory markers and risk of heart failure in elderly subjects without myocardial infarction: the Framingham Heart Study","volume":"107","author":"Vasan","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0875","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.203","article-title":"Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial","volume":"17","author":"Edelmann","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"7","key":"10.1016\/j.bcp.2024.116232_b0880","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate immunity and the failing heart: the cytokine hypothesis revisited","volume":"116","author":"Mann","year":"2015","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0885","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","article-title":"Chronic heart failure and inflammation: What do we really know?","volume":"119","author":"Dick","year":"2016","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0890","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10557-020-07071-0","article-title":"Inflammatory cytokines and chemokines as therapeutic targets in heart failure","volume":"34","author":"Hanna","year":"2020","journal-title":"Cardiovasc Drug Ther."},{"issue":"25","key":"10.1016\/j.bcp.2024.116232_b0895","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","article-title":"Safety and efficacy of a soluble P75 tumor necrosis receptor (Enbrel, etanercept) in patients with advanced heart failure","volume":"99","author":"Deswal","year":"1999","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.bcp.2024.116232_b0900","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with estanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.bcp.2024.116232_b0905","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: result of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.bcp.2024.116232_b0910","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.bcp.2024.116232_b0915","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.3390\/jcm9103267","article-title":"Complexity of TNF-\u03b1 signaling in heart disease","volume":"9","author":"Rolski","year":"2020","journal-title":"J. Clin. Med."},{"issue":"9608","key":"10.1016\/j.bcp.2024.116232_b0920","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(08)60134-8","article-title":"Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Investigators, Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial","volume":"371","author":"Torre-Amione","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b0925","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"CANTOS Trial Group, Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b0930","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ijms24010017","article-title":"The IL-1 family and its role in atherosclerosis","volume":"24","author":"Gonz\u00e1lez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2024.116232_b0935","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.bcp.2024.116232_b0940","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0945","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bcp.2024.116232_b0950","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ehf2.12744","article-title":"The role of B cells in heart failure and implications for future immunomodulatory treatment strategies","volume":"7","author":"Garc\u00eda-Rivas","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0955","first-page":"901","article-title":"Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient","volume":"39","author":"Aggarwal","year":"2012","journal-title":"Tex. Heart Inst. J."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0960","doi-asserted-by":"crossref","first-page":"e022826","DOI":"10.1136\/bmjopen-2018-022826","article-title":"Phase II clinical trials testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICEFr-RITU2: study protocol","volume":"9","author":"S\u00e1nchez-Trujillo","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.bcp.2024.116232_b0965","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/5584_2019_463","article-title":"The horizon of gene therapy in modern medicine: Advances and challenges","volume":"1247","author":"Arjmand","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b0970","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/CIRCRESAHA.108.173195","article-title":"Gene therapy in heart failure","volume":"102","author":"Vinge","year":"2008","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0975","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","volume":"15","author":"Jaski","year":"2009","journal-title":"J. Card. Fail."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0980","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b0985","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cvr\/cvm056","article-title":"Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology","volume":"77","author":"Periasamy","year":"2008","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b0990","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.RES.75.3.434","article-title":"Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium","volume":"75","author":"Hasenfus","year":"1994","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.bcp.2024.116232_b0995","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00207509","article-title":"Sarcoplasmic reticulum Ca2+ ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy","volume":"74","author":"Flesch","year":"1996","journal-title":"J. Mol. Med. (Berl)"},{"issue":"10024","key":"10.1016\/j.bcp.2024.116232_b1000","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bcp.2024.116232_b1005","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/ejhf.826","article-title":"AGENT-HF Investigators, Effect of intracoronary administration of AAV1\/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial","volume":"19","author":"Hulot","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b1010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","article-title":"Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device \u2013 the SERCA-LVAD TRIAL","volume":"27","author":"Lyon","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcp.2024.116232_b1015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.coviro.2014.07.008","article-title":"Adeno-associated virus: Fit to serve","volume":"8","author":"Zinn","year":"2014","journal-title":"Curr. Opin. Virol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b1020","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: An overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b1025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1752-8062.2010.00190.x","article-title":"Comparative cardiac gene delivery of adeno-associated virus serotypes 1\u20139 reveals that AAV6 mediates the most efficient transduction in mouse heart","volume":"3","author":"Zincarelli","year":"2010","journal-title":"Clin. Transl. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2024.116232_b1030","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/mt.2015.158","article-title":"Gene therapy for heart failure: Back to the bench","volume":"23","author":"Yl\u00e4-Herttuala","year":"2015","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b1035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nbt.1599","article-title":"Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle","volume":"28","author":"Asokan","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2024.116232_b1040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658399","article-title":"Anti-AAV antibodies in AAV gene therapy: Current challenges and possible solutions","volume":"12","author":"Weber","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2024.116232_b1045","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/01.RES.0000161256.85833.fa","article-title":"Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1","volume":"96","author":"Pathak","year":"2005","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.bcp.2024.116232_b1050","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/CIRCRESAHA.111.259754","article-title":"Modulation of cardiac contractility by the phospholamban\/SERCA2a regulatome","volume":"110","author":"Kranias","year":"2012","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.bcp.2024.116232_b1055","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/CIRCRESAHA.108.189811","article-title":"Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia\/reperfusion injury","volume":"104","author":"Nicolaou","year":"2009","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b1060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCHEARTFAILURE.112.971325","article-title":"AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling","volume":"6","author":"Fish","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.bcp.2024.116232_b1065","doi-asserted-by":"crossref","unstructured":"A. Cannat\u00e0, H. Ali, G. Sinagra, M. Giacca, Gene therapy for the heart lessens learned and future perspectives. Circ Res. 126 (10) 1394-1414.","DOI":"10.1161\/CIRCRESAHA.120.315855"},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b1070","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1152\/physrev.00013.2021","article-title":"Physiological roles of mammalian transmembrane adenylyl cyclase isoforms","volume":"102","author":"Ostrom","year":"2022","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b1075","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1124\/jpet.109.150953","article-title":"Characterization of mouse heart adenylyl cyclase","volume":"329","author":"G\u00f6ttle","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b1080","first-page":"H707","article-title":"Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload","volume":"299","author":"Guellich","year":"2010","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"issue":"16","key":"10.1016\/j.bcp.2024.116232_b1085","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/CIRCULATIONAHA.107.698662","article-title":"Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress","volume":"116","author":"Okumura","year":"2007","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.bcp.2024.116232_b1090","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1172\/JCI117219","article-title":"Downregulation of adenylylcyclase type V and VI mRNA levels in pacing-induced heart failure in dogs","volume":"93","author":"Ishikawa","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"16","key":"10.1016\/j.bcp.2024.116232_b1095","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/01.CIR.0000014968.54967.D3","article-title":"Adenylyl cyclase increases survival in cardiomyopathy","volume":"105","author":"Roth","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2024.116232_b1100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.yjmcc.2006.04.008","article-title":"Cardiac-directed expression of adenylyl cyclase reverses electrical remodeling in cardiomyopathy","volume":"41","author":"Timofeyev","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116232_b1105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/01.CIR.0000136033.21777.4D","article-title":"Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure","volume":"110","author":"Lai","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcp.2024.116232_b1110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: A randomized clinical trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.bcp.2024.116232_b1115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ahj.2018.04.005","article-title":"Design of a phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH clinical trial","volume":"201","author":"Penny","year":"2018","journal-title":"Am. Heart J."},{"issue":"18","key":"10.1016\/j.bcp.2024.116232_b1120","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for management of heart failure: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.bcp.2024.116232_b1125","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: A report of the American College of Cardiology solution set overnight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224002156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224002156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:49:31Z","timestamp":1778636971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224002156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":225,"alternative-id":["S0006295224002156"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116232","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenging and target-based shifting strategies for heart failure treatment: An update from the last decades","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116232"}}